🇺🇸 FDA

Company profile · Sponsor

Atea

Atea Pharmaceuticals

AVIR · NYSE pharma BOSTON, MA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

Atea (AVIR) is a pharma company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker AVIR
Exchange NYSE
Company type pharma
Headquarters BOSTON, MA, USA
SEC CIK 0001593899

Pipeline (24)

Search pipeline →

  1. Bemnifosbuvir (BEM)

    Atea

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)

    phase 3 small molecule completed

    1 trial

  2. Bemnifosbuvir-Ruzasvir

    Atea

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  3. Bemnifosbuvir-Ruzasvir (BEM/RZR)

    Atea

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  4. Bemnifosbuvir/Ruzasvir Fixed Dose Combination (FDC), Sofosbuvir / Velpatasvir

    Atea

    Chronic Hepatitis C Virus (HCV) Infection

    phase 3 small molecule active

    1 trial

  5. RO7496998

    Atea

    COVID-19

    phase 3 small molecule terminated

    1 trial

  6. AT-527

    Atea

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  7. AT-527

    Atea

    COVID-19

    phase 2 small molecule terminated

    2 trials

  8. AT-752

    Atea

    Dengue Fever

    phase 2 small molecule terminated

    1 trial

  9. AT-777

    Atea

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  10. Bemnifosbuvir

    Atea

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    1 trial

  11. GHB11L1

    Atea

    Influenza, Human

    phase 2 mab completed

    1 trial

  12. GHB16L2

    Atea

    Influenza, Human

    phase 2 mab completed

    1 trial

  13. AT-527

    Atea

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  14. AT-527

    Atea

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  15. AT-527

    Atea

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  16. AT-527 (R07496998)

    Atea

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  17. AT-527 + digoxin

    Atea

    Healthy Volunteers Study

    phase 1 small molecule completed

    1 trial

  18. AT-527 550 mg + cyclosporine

    Atea

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  19. AT-527 550 mg + midazolam

    Atea

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  20. AT-527 Formulation 1

    Atea

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  21. AT-527 fasted

    Atea

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  22. AT-752

    Atea

    Dengue

    phase 1 small molecule completed

    2 trials

  23. Bemnifosbuvir (BEM)

    Atea

    Healthy Volunteer Study

    phase 1 small molecule completed

    2 trials

  24. Bemnifosbuvir (BEM)

    Atea

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12226429

    Highly active compounds against COVID-19

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12084473

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12006340

    Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12005139

    Ophthalmic formulations and related methods

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11975016

    2′-substituted-N6-substituted purine nucleotides for RNA virus treatment

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11964047

    Ophthalmic formulations and related methods

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11833160

    Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11813278

    Highly active compounds against COVID-19

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Atea?

Atea (AVIR) is a pharma company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Atea sponsor?

We track 24 ClinicalTrials.gov-linked programs for Atea, including Bemnifosbuvir (BEM) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Atea company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.